Skip to main content

Table 2 Schedules of treatment in patients with HBV or HCV infection

From: Lack of evidence of viral reactivation in HBsAg-negative HBcAb-positive and HCV patients undergoing immunosuppressive therapy for psoriasis

Schedules of treatment [#] Isolated HBcAb positive (23 patients) HBcAb/HBsAb positive (36 patients) HCV-Ab positive (15 patients)
Conventional therapy    
  MTX, n. 3 5 0
  Duration, months (mean ± SD) 11 ± 7,54 24 ± 23,62 -
  Cyclosporine, n. 0 4 4
  Duration, months (mean ± SD) - 5,75 ± 4,5 20,25 ± 10,34
  MTX + Cyclosporine, n. 2 5 5
  Duration, months (mean ± SD) 12 26,4 ± 21,46 30,4 ± 22,19
Conventional > Biological * therapy, n. 16 18 6
  Duration, months (mean ± SD) 33,8 ± 16,9 48,1 ± 26,55 46 ± 34,77
Conventional > Biological * therapy + MTX, n. 2 4 0
  Duration, months (mean ± SD) 35,5 ± 4,94 90,75 ± 65,06 -
  1. *Adalimumab, etanercept, infliximab, golimumab, ustekinumab.
  2. [#] The treatment schedule was standardized, the doses were used as follows.
  3. MTX (7.5 vs15 mg/ week -per os or intramuscular injections).
  4. Cyclosporine (2.5 vs 5 mg/prokilo/die- per os).
  5. Adalimumab (40 mg every other week-subcutaneous injections).
  6. Etanercept (50 mg weekly- subcutaneous injections).
  7. Infliximab (5 mg/kg at 0, 2 and 6 weeks, then every 8 weeks-endovenous infusion).
  8. Golimumab (50 mg monthly-subcutaneus injections).
  9. Ustekinumab ( For patients weighing ≤100 kg (220 lbs), the recommended dose is 45 mg initially and 4 weeks later, followed by 45 mg every 12 weeks. For patients weighing >100 kg (220 lbs), the recommended dose is 90 mg initially and 4 weeks later, followed by 90 mg every 12 weeks. – subcutaneous injections).
  10. The data in bold represent "macro-categories", while the data not in bold represent their "sub-categories".